MedCity News

NOVEMBER 25, 2024

BridgeBio Pharma claims its drug, Attruby, has an edge over a Pfizer drug as a treatment for cardiomyopathy caused by transthyretin-mediated amyloidosis. But new competition to both products could come soon from Alnylam Pharmaceuticals, now set to receive an FDA decision in this indication by late March.

Competition 305

Competition FDA Pharma Pharmaceutical 305

MedCity News

JANUARY 12, 2025

Gilead Sciences is acquiring LEO Pharmas oral small molecule inhibitors of STAT6, a protein key to two validated inflammation pathways. Other STAT6 drug developers include Kymera Therapeutics and Sanofi-partnered Recludix Pharma, which is presenting this week during the J.P. Morgan Healthcare Conference.

Pharma 263

Pharma Healthcare Healthcare Biopharma 263

MedCity News

MARCH 17, 2025

AstraZenecas EsoBiotec acquisition is the latest in a series of deals struck by the pharma giant to secure a place in the next wave of cell therapies for cancer and immune-mediated diseases. EsoBiotecs allogeneic cell therapies are made by the in vivo reprogramming of a patients immune cells.

Pharma 278

Pharma Patients Biopharma 278

MedCity News

OCTOBER 9, 2024

If you thought that Big Pharma and the PBMs were the only bad guys in the saga of unreasonably high prescription drug prices in the United States, you would be wrong. The post Video: Besides, Pharma and PBMs, Who Drives Up Drug Costs? Hear who else is to blame from the CEO of Blue Shield of California.

Pharma 320

Pharma Prescription 320

Impetus Digital

DECEMBER 23, 2024

Pharma-exclusive Webinar: The 2025 Pharma Toolkit for Virtual Medical Education About the webinar Step into the future of medical education with our exclusive webinar series from February 25-26, designed specifically for Pharma leaders.

Education 110

Education Medical Pharma Training 110

MedCity News

JANUARY 23, 2025

Astellas Pharma still looks to grow in cancer with a pipeline that includes internally developed programs that could stand out in oncology. But the drugmaker sees additional growth opportunities in ophthalmology and neuromuscular disorders, Chief Medical Officer Tadaaki Taniguci said.

Pharma 278

Pharma Medical Biopharma 278

MedCity News

MARCH 12, 2025

Roche will share in developing and commercializing petrelintide, a clinical-stage Zealand Pharma drug that activates the amylin receptor to spark weight loss. This agreement represents the highest total financial consideration in the obesity field to date.

Pharma 236

Pharma Biopharma 236

MedCity News

FEBRUARY 19, 2025

The post Recursion Pharma Accelerator Steps In to Fill Some of the Funding Gap Amid NIH Tumult appeared first on MedCity News. Altitude Lab Fund will provide pre-seed funding for early-stage startups affected by changes to grant programs administered by the National Institutes of Health.

Pharma 165

Pharma Pharmaceutical Biopharma 165

MedCity News

JANUARY 31, 2025

The post Vertex Pharmas Opioid Alternative Wins FDA Approval, First in a New Class of Pain Meds appeared first on MedCity News. Vertex Pharmaceuticals Jounavx is now FDA approved, providing patients a non-opioid option for treating acute pain.

FDA 276

FDA Medicine Pharma Pharmaceutical 276

MedCity News

OCTOBER 21, 2024

The post Astellas Pharma Lands a First-in-Class Drug Approval in Rare Gastrointestinal Cancer appeared first on MedCity News. The FDA approved Astellas’s Vyloy as a treatment for advanced cases of gastric or gastroesophageal junction (GEJ) adenocarcinoma positive for a protein called claudin 18.2.

Pharma 328

Pharma FDA Biopharma 328

MedCity News

OCTOBER 14, 2024

Longboard Pharma Acquisition appeared first on MedCity News. Last month, the biotech began a Phase 3 clinical trial testing the drug in Dravet syndrome. The post Lundbeck’s Neuro-Rare Pipeline Lands Cornerstone Drug via $2.6B

Pharma 316

Pharma Pharmaceutical Biopharma 316

Fierce Pharma

NOVEMBER 1, 2024

said in an interview with Fierce Pharma. Now, less than a year later, the FDA is reconsidering those serious safety warnings with plans to potentially change them, CBER Director Peter Marks, M.D.,

FDA 284

FDA Safety Pharma Patients 284

MedCity News

NOVEMBER 4, 2024

This product candidate will be developed with Ascendis Pharma technology that has already yielded two FDA-approved products with longer dosing intervals. The Novo Nordisk/Ascendis partnership’s lead program is once-monthly injectable semaglutide for type 2 diabetes and obesity.

Pharma 305

Pharma FDA Leads Biopharma 305

MedCity News

SEPTEMBER 16, 2024

The post New Eli Lilly Eczema Drug Brings Competition and Dosing Edge Versus Sanofi, LEO Pharma Meds appeared first on MedCity News. Eli Lilly drug Ebglyss is now FDA-approved for atopic dermatitis, an inflammatory skin disorder also known as eczema. The biologic drug came from Lilly’s $1.1 billion acquisition of Dermira in 2020.

Competition 317

Competition Pharma FDA Biopharma 317

MedCity News

OCTOBER 20, 2024

The post How Generative AI Will Find a Place in the Pharma Industry Now and in the Years to Come appeared first on MedCity News. Pharmaceutical and biotech companies are using generative AI to predict drug-target interactions, optimize lead compounds, and generate novel molecular structures.

Pharma 331

Pharma Leads Pharmaceutical Biopharma 331

MedCity News

OCTOBER 15, 2024

PurpleLab® stands out from others in this sector by providing its data analytics services to several different groups of users across healthcare and pharma companies. The post The Future of Hospitals and Pharma Companies Will Depend on Strength of Healthcare Analytics Insights appeared first on MedCity News.

Healthcare 297

Healthcare Healthcare Pharma Pharmaceutical 297

PharmaVoice

MARCH 21, 2025

Pharma has long been considered “recession proof,” but an economic downturn could still hurt the industry in numerous ways.

Pharma 243

Pharma 243

MedCity News

SEPTEMBER 24, 2024

The post Pain Meds, Cell Therapies & More: Vertex Pharma CEO Talks About What’s Next After Cystic Fibrosis appeared first on MedCity News. Vertex Pharmaceuticals is known for its cystic fibrosis drugs, but the company aims to diversify with a pipeline that reaches more therapeutic areas.

Pharma 306

Pharma Pharmaceutical Medical Biopharma 306

MedCity News

MARCH 24, 2025

Separately, the pharma giant said its recently announced discounted price for obesity medication Wegovy is now expanding to traditional pharmacies. Novo Nordisk is licensing rights to a United Biotechnology drug that sparks metabolic effects by binding to and activating receptors for GLP-1, GIP, and glucagon.

Pharma 232

Pharma Medical Biopharma 232

PharmaVoice

JANUARY 3, 2025

Pharma companies stepped up to support The Carter Center and provide access to life-saving treatments.

Pharma 278

Pharma 278

Fierce Pharma

OCTOBER 23, 2024

The war is on between compounding pharmacies making knockoff versions of popular weight loss drugs and pharma giants Novo Nordisk and Eli Lilly, who want to protect their right to sell their patent | Novo Nordisk has asked the FDA to prevent compounders from manufacturing copycat versions of its juggernaut diabetes and obesity treatments Ozempic and (..)

FDA 249

FDA Manufacturing Pharma 249

PharmaVoice

FEBRUARY 12, 2025

As drug development priorities shift, pharma companies need to understand younger patients to improve their reputation.

Pharma 262

Pharma Patients 262

MedCity News

DECEMBER 16, 2024

Separately, the pharma giant said all regulatory conditions have been met for Novo Holdings acquisition of Catalent, which will bring to Novo Nordisk three manufacturing sites for GLP-1 medications. Novo Nordisks new Denmark site will produce drugs for rare diseases, such as hemophilias.

Manufacturing 262

Manufacturing Pharma Medical Biopharma 262

Evolve Your Success

FEBRUARY 5, 2025

Heres How Join the Medical Sales Podcast Community today: evolveyoursuccess.com This Podcast offers a pathway to continuing education via this CMEfy link: [link] The post Why I Went From Abbot Pharma Sales to 1099 With Bruce Brown first appeared on Evolve Your Success.

Sales 130

Sales Medical sales Pharma Medical 130

MedCity News

JANUARY 24, 2025

Ascentage Pharmas U.S. IPO will support clinical testing of its two lead drugs, small molecules in development for advanced cases of certain blood cancers. Takeda holds an exclusive option to develop and commercialize one of those drugs in most of the world. The post Ascentage Has First U.S.

Pharma 238

Pharma Leads Biopharma 238

Fierce Pharma

DECEMBER 2, 2024

Shortly after a similarly sized venture from Pfizer, French pharma juggernaut Sanofi has unveiled a major manufacturing outlay in China, marking its biggest investment in the country to date. Sanofi is laying out roughly 1 billion euros ($1.04

Manufacturing 232

Manufacturing Pharma 232

MedCity News

MARCH 25, 2025

Apellis Pharmaceuticals and Astellas Pharma have the first two FDA-approved therapies for geographic atrophy, but Character Biosciences claims its approach could be best in class for treating this advanced form of dry age-related macular degeneration.

Pharma 179

Pharma FDA Pharmaceutical Biopharma 179

Fierce Pharma

OCTOBER 23, 2024

While Regeneron may have lost its latest bid to block the launch of Amgen’s Eylea biosimilar Pavblu, the New York-based pharma isn’t throwing in the towel just yet. Amgen is preparing to launch its Eylea biosimilar, Pavblu, after another victory over Regeneron in court.

Pharma 215

Pharma 215

Fierce Pharma

OCTOBER 11, 2024

With reports swirling about potential interest in Sanofi’s consumer health business, the French pharma has confirmed that a deal is indeed brewing. Sanofi has entered negotiations with private equity outfit Clayton, Dubilier & Rice to potentially sell a 50% controlling stake in its consumer health business, Opella.

Pharma 195

Pharma 195

Pharma Marketing Network

MARCH 25, 2025

Automation, AI, budget cuts, and evolving digital strategies have prompted a growing question among pharmaceutical marketing teams: Is my pharma marketing job at risk? Understanding how to future-proof your pharma marketing job starts with identifying the forces driving changeand how you can evolve with them.

Marketing 59

Marketing Pharma Networking Media 59

Fierce Pharma

NOVEMBER 26, 2024

German CDMO Adragos Pharma has been on a growth tear this year, drafting plans to boost capacity in Japan, upgrading a facility in France, taking over another from Fresenius Kabi in Norway and more | German CDMO Adragos Pharma has been on a growth tear this year.

Specialization 175

Specialization Networking Pharma Manufacturing 175

MedCity News

FEBRUARY 26, 2025

From the executive boardrooms of pharma companies to academic research centers, one fact is becoming unmistakably clear: making radiopharmaceuticals is an inherently complex, high-stakes endeavor, and the industry is racing to manage the risks of these perishable therapies before the clock runs out The post Radiopharmaceutical Manufacturing: A High-Stakes (..)

Manufacturing 191

Manufacturing Pharma Management Biopharma 191

Pharma Marketing Network

MARCH 28, 2025

Introduction Weekends may be synonymous with relaxation, but for pharma marketing professionals, they offer an unmatched window to recalibrate. The Pharma Marketing Network serves as an ideal destination for this kind of weekend deep-dive. Theyre tailored, actionable, and grounded in real-world pharma marketing dynamics.

Networking 59

Networking Marketing Pharma Media 59

Fierce Pharma

OCTOBER 23, 2024

Now, a new complaint has surfaced—not from lawmakers or consumer groups but a major pharma CEO. While Novo Holdings and Catalent continue to voice confidence that their planned $16.5 billion merger will go through before the year is out, the deal has received near-constant criticism over the past several weeks.

Pharma 203

Pharma 203

Fierce Pharma

SEPTEMBER 25, 2024

billion acquisition the New York pharma made two years ago. Pfizer will voluntarily pull its sickle cell disease drug Oxbryta from all markets worldwide, a major blow to a $5.4 Pfizer will voluntarily pull its sickle cell disease drug Oxbryta from all markets worldwide, a major blow to its $5.4

Marketing 321

Marketing Pharma 321

MedCity News

SEPTEMBER 27, 2024

The drug came from the pharma giant’s $14 billion acquisition of Karuna Therapeutics. Bristol Myers Squibb’s Cobenfy treats schizophrenia by going after a different target than currently available antipsychotic drugs, which is intended to offer better efficacy and safety.

FDA 312

FDA Safety Pharma Biopharma 312

Fierce Pharma

OCTOBER 1, 2024

Johnson & Johnson is laying off 231 employees in New Jersey and Bayer is cutting 57 positions in the state, according to separate Worker Adjustment and Retraining Notification (WARN)

Pharma 318

Pharma 318